Roche

(IN BRIEF) Roche has agreed to acquire PathAI to strengthen its digital pathology and AI-powered diagnostics capabilities. The deal builds on an existing partnership between the companies focused on AI-enabled companion diagnostics and pathology solutions. Roche said the acquisition will … Read the full press release →

(IN BRIEF) Roche has reached a key regulatory milestone with the FDA’s acceptance of its application for Gazyva/Gazyvaro as a treatment for systemic lupus erythematosus. The submission is based on strong phase III trial data showing significant improvements in disease … Read the full press release →

(IN BRIEF) Roche has obtained CE mark approval for its Elecsys Neurofilament Light Chain blood test, which detects neuroinflammation in patients with relapsing-remitting multiple sclerosis. The minimally invasive test measures biomarkers of nerve damage, offering an alternative to traditional monitoring … Read the full press release →

(IN BRIEF) New data presented at EHRA 2026 show that individuals with atrial fibrillation detected through screening face a threefold higher risk of developing heart failure compared with those without AF, with a risk level similar to patients with known … Read the full press release →

(IN BRIEF) Roche has launched the cobas MPX-E assay, a multiplex molecular diagnostic test capable of detecting HIV, Hepatitis B, Hepatitis C, and Hepatitis E simultaneously in a single workflow. Available in CE mark–accepting markets, the assay is designed to … Read the full press release →

(IN BRIEF) Roche has appointed physician-scientist Mark Dawson as Head of Pharma Research and Early Development, effective 1 May 2026, with the role based in Basel and including membership on the Enlarged Corporate Executive Committee. Dawson brings extensive expertise in … Read the full press release →

(IN BRIEF) Roche reported that its phase III MAJESTY trial met its primary endpoint, showing that treatment with Gazyva/Gazyvaro enabled significantly more patients with primary membranous nephropathy to achieve complete remission at two years compared with tacrolimus. The study also … Read the full press release →